ATC code L01: Difference between revisions

From WikiMD's Wellness Encyclopedia

No edit summary
 
CSV import
Line 1: Line 1:
{{ATC codes lead|L|01|Antineoplastic agents|vet=add}}
{{DISPLAYTITLE:ATC Code L01}}
{{Infobox drug class
| ATC_code = L01
| ATC_suffix =
| ATC_prefix = L
| ATC_supplemental =
| image =
| width =
| caption =  
}}


=={{anchor|L01A}}L01A [[Alkylating agent]]s==
== Introduction ==
'''ATC code L01''' is a classification used in the [[Anatomical Therapeutic Chemical Classification System]] to categorize [[antineoplastic agents]]. These are drugs used in the treatment of [[cancer]], and they work by inhibiting the growth and spread of [[malignant cells]]. The ATC system is maintained by the [[World Health Organization]] (WHO) and is used globally to ensure uniformity in the classification of drugs.


==={{anchor|L01AA}}L01AA [[Nitrogen mustard]] analogues===
== Classification ==
:L01AA01 [[Cyclophosphamide]]
ATC code L01 is divided into several subgroups based on the mechanism of action and chemical structure of the antineoplastic agents. These subgroups include:
:L01AA02 [[Chlorambucil]]
:L01AA03 [[Melphalan]]
:L01AA05 [[Chlormethine]]
:L01AA06 [[Ifosfamide]]
:L01AA07 [[Trofosfamide]]
:L01AA08 [[Prednimustine]]
:L01AA09 [[Bendamustine]]


==={{anchor|L01AB}}L01AB Alkyl sulfonates===
=== L01A: Alkylating Agents ===
:L01AB01 [[Busulfan]]
Alkylating agents work by adding an alkyl group to the [[DNA]] of cancer cells, which interferes with their replication and leads to cell death. Common drugs in this category include:
:L01AB02 [[Treosulfan]]
* [[Cyclophosphamide]]
:L01AB03 [[Mannosulfan]]
* [[Ifosfamide]]
* [[Melphalan]]


==={{anchor|L01AC}}L01AC Ethylene imines===
=== L01B: Antimetabolites ===
:L01AC01 [[Thiotepa]]
Antimetabolites resemble natural substances within the cell, thus interfering with normal cellular processes. They are particularly effective during the [[S phase]] of the cell cycle. Examples include:
:L01AC02 [[Triaziquone]]
* [[Methotrexate]]
:L01AC03 [[Carboquone]]
* [[5-Fluorouracil]]
* [[Cytarabine]]


==={{anchor|L01AD}}L01AD [[Nitrosourea]]s===
=== L01C: Plant Alkaloids and Other Natural Products ===
:L01AD01 [[Carmustine]]
These agents are derived from plants and work by disrupting the [[mitotic spindle]] formation, thus inhibiting cell division. Notable drugs include:
:L01AD02 [[Lomustine]]
* [[Vincristine]]
:L01AD03 [[Semustine]]
* [[Vinblastine]]
:L01AD04 [[Streptozocin]]
* [[Paclitaxel]]
:L01AD05 [[Fotemustine]]
:L01AD06 [[Nimustine]]
:L01AD07 [[Ranimustine]]
:L01AD08 [[Uramustine]]


==={{anchor|L01AG}}L01AG [[Epoxide]]s===
=== L01D: Cytotoxic Antibiotics and Related Substances ===
:L01AG01 [[Etoglucid]]
Cytotoxic antibiotics are compounds that have antibiotic properties but are used in cancer treatment due to their ability to damage the DNA of cancer cells. Examples are:
* [[Doxorubicin]]
* [[Bleomycin]]
* [[Mitomycin]]


==={{anchor|L01AX}}L01AX Other alkylating agents===
=== L01E: Protein Kinase Inhibitors ===
:L01AX01 [[Mitobronitol]]
These inhibitors target specific [[protein kinases]] involved in the signaling pathways that regulate cell division and survival. They are a part of targeted cancer therapies. Examples include:
:L01AX02 [[Pipobroman]]
* [[Imatinib]]
:L01AX03 [[Temozolomide]]
* [[Erlotinib]]
:L01AX04 [[Dacarbazine]]
* [[Sunitinib]]


=={{anchor|L01B}}L01B [[Antimetabolite]]s==
=== L01X: Other Antineoplastic Agents ===
This category includes antineoplastic agents that do not fit into the other categories. Examples include:
* [[Hydroxyurea]]
* [[Mitotane]]
* [[Procarbazine]]


==={{anchor|L01BA}}L01BA [[Folic acid]] analogues===
== Mechanism of Action ==
:L01BA01 [[Methotrexate]]
Antineoplastic agents work through various mechanisms to inhibit the proliferation of cancer cells. These mechanisms include:
:L01BA03 [[Raltitrexed]]
* [[DNA alkylation]] and cross-linking
:L01BA04 [[Pemetrexed]]
* Inhibition of [[nucleotide synthesis]]
:L01BA05 [[Pralatrexate]]
* Disruption of [[microtubule function]]
* Inhibition of [[topoisomerase]] enzymes
* Targeting specific [[molecular pathways]] involved in cancer cell growth


==={{anchor|L01BB}}L01BB [[Purine]] analogues===
== Clinical Use ==
:L01BB02 [[Mercaptopurine]]
Antineoplastic agents are used in the treatment of various types of cancer, including but not limited to:
:L01BB03 [[Tioguanine]]
* [[Breast cancer]]
:L01BB04 [[Cladribine]]
* [[Lung cancer]]
:L01BB05 [[Fludarabine]]
* [[Leukemia]]
:L01BB06 [[Clofarabine]]
* [[Lymphoma]]
:L01BB07 [[Nelarabine]]
* [[Colorectal cancer]]
:QL01BB90 [[Rabacfosadine]]


==={{anchor|L01BC}}L01BC [[Pyrimidine]] analogues===
The choice of agent depends on the type of cancer, stage of disease, and the patient's overall health status.
:L01BC01 [[Cytarabine]]
:L01BC02 [[Fluorouracil]]
:L01BC03 [[Tegafur]]
:L01BC04 [[Carmofur]]
:L01BC05 [[Gemcitabine]]
:L01BC06 [[Capecitabine]]
:L01BC07 [[Azacitidine]]
:L01BC08 [[Decitabine]]
:L01BC09 [[Floxuridine]]
:L01BC52 Fluorouracil, combinations
:L01BC53 Tegafur, combinations
:L01BC59 [[Trifluridine]], combinations


=={{anchor|L01C}}L01C Plant [[alkaloid]]s and other natural products==
== Side Effects ==
The use of antineoplastic agents is associated with a range of side effects due to their impact on rapidly dividing cells. Common side effects include:
* [[Myelosuppression]]
* [[Nausea and vomiting]]
* [[Alopecia]]
* [[Mucositis]]
* [[Fatigue]]


==={{anchor|L01CA}}L01CA [[Vinca]] alkaloids and analogues===
== Conclusion ==
:L01CA01 [[Vinblastine]]
ATC code L01 encompasses a diverse group of drugs that are essential in the management of cancer. Understanding their classification, mechanism of action, and clinical application is crucial for optimizing cancer treatment and improving patient outcomes.
:L01CA02 [[Vincristine]]
:L01CA03 [[Vindesine]]
:L01CA04 [[Vinorelbine]]
:L01CA05 [[Vinflunine]]
:L01CA06 [[Vintafolide]]


==={{anchor|L01CB}}L01CB [[Podophyllotoxin]] derivatives===
== References ==
:L01CB01 [[Etoposide]]
* World Health Organization. "ATC/DDD Index 2023." Accessed October 2023.
:L01CB02 [[Teniposide]]
* National Cancer Institute. "Cancer Drug Information." Accessed October 2023.


==={{anchor|L01CC}}L01CC [[Colchicine]] derivatives===
== See Also ==
:L01CC01 [[Demecolcine]]
* [[Anatomical Therapeutic Chemical Classification System]]
* [[Cancer treatment]]
* [[Chemotherapy]]


==={{anchor|L01CD}}L01CD [[Taxane]]s===
[[Category:ATC codes]]
:L01CD01 [[Paclitaxel]]
[[Category:Antineoplastic agents]]
:L01CD02 [[Docetaxel]]
[[Category:Cancer treatments]]
:L01CD03 [[Paclitaxel poliglumex]]
:L01CD04 [[Cabazitaxel]]
 
==={{anchor|L01CX}}L01CX Other plant alkaloids and natural products===
:L01CX01 [[Trabectedin]]
 
=={{anchor|L01D}}L01D [[Cytotoxic antibiotics]] and related substances==
 
==={{anchor|L01DA}}L01DA [[Actinomycine]]s===
:L01DA01 [[Dactinomycin]]
 
==={{anchor|L01DB}}L01DB [[Anthracycline]]s and related substances===
:L01DB01 [[Doxorubicin]]
:L01DB02 [[Daunorubicin]]
:L01DB03 [[Epirubicin]]
:L01DB04 [[Aclarubicin]]
:L01DB05 [[Zorubicin]]
:L01DB06 [[Idarubicin]]
:L01DB07 [[Mitoxantrone]]
:L01DB08 [[Pirarubicin]]
:L01DB09 [[Valrubicin]]
:L01DB10 [[Amrubicin]]
:L01DB11 [[Pixantrone]]
 
==={{anchor|L01DC}}L01DC Other cytotoxic antibiotics===
:L01DC01 [[Bleomycin]]
:L01DC02 [[Plicamycin]]
:L01DC03 [[Mitomycin]]
:L01DC04 [[Ixabepilone]]
 
=={{anchor|L01X}}L01X Other antineoplastic agents==
 
==={{anchor|L01XA}}L01XA [[Platinum]] compounds===
:L01XA01 [[Cisplatin]]
:L01XA02 [[Carboplatin]]
:L01XA03 [[Oxaliplatin]]
:L01XA04 [[Satraplatin]]
:L01XA05 [[Polyplatillen]]
 
==={{anchor|L01XB}}L01XB [[Methylhydrazine]]s===
:L01XB01 [[Procarbazine]]
 
==={{anchor|L01XC}}L01XC [[Monoclonal antibodies]]===
:L01XC01 [[Edrecolomab]]
:L01XC02 [[Rituximab]]
:L01XC03 [[Trastuzumab]]
:L01XC05 [[Gemtuzumab ozogamicin]]
:L01XC06 [[Cetuximab]]
:L01XC07 [[Bevacizumab]]
:L01XC08 [[Panitumumab]]
:L01XC09 [[Catumaxomab]]
:L01XC10 [[Ofatumumab]]
:L01XC11 [[Ipilimumab]]
:L01XC12 [[Brentuximab vedotin]]
:L01XC13 [[Pertuzumab]]
:L01XC14 [[Trastuzumab emtansine]]
:L01XC15 [[Obinutuzumab]]
:L01XC16 [[Dinutuximab beta]]
:L01XC17 [[Nivolumab]]
:L01XC18 [[Pembrolizumab]]
:L01XC19 [[Blinatumomab]]
:L01XC21 [[Ramucirumab]]
:L01XC22 [[Necitumumab]]
:L01XC23 [[Elotuzumab]]
:L01XC24 [[Daratumumab]]
:L01XC25 [[Mogamulizumab]]
:L01XC26 [[Inotuzumab ozogamicin]]
:L01XC27 [[Olaratumab]]
:L01XC28 [[Durvalumab]]
:L01XC29 [[Bermekimab]]
:L01XC31 [[Avelumab]]
:L01XC32 [[Atezolizumab]]
 
==={{anchor|L01XD}}L01XD [[Photosensitizer|Sensitizers]] used in [[photodynamic therapy|photodynamic]]/[[Radiation therapy|radiation]] therapy===
:L01XD01 [[Porfimer sodium]]
:L01XD03 [[Methyl aminolevulinate]]
:L01XD04 [[Aminolevulinic acid]]
:L01XD05 [[Temoporfin]]
:L01XD06 [[Efaproxiral]]
:L01XD07 [[Padeliporfin]]
 
==={{anchor|L01XE}}L01XE [[Protein kinase inhibitors]]===
:L01XE01 [[Imatinib]]
:L01XE02 [[Gefitinib]]
:L01XE03 [[Erlotinib]]
:L01XE04 [[Sunitinib]]
:L01XE05 [[Sorafenib]]
:L01XE06 [[Dasatinib]]
:L01XE07 [[Lapatinib]]
:L01XE08 [[Nilotinib]]
:L01XE09 [[Temsirolimus]]
:L01XE10 [[Everolimus]]
:L01XE11 [[Pazopanib]]
:L01XE12 [[Vandetanib]]
:L01XE13 [[Afatinib]]
:L01XE14 [[Bosutinib]]
:L01XE15 [[Vemurafenib]]
:L01XE16 [[Crizotinib]]
:L01XE17 [[Axitinib]]
:L01XE18 [[Ruxolitinib]]
:L01XE19 [[Ridaforolimus]]
:L01XE21 [[Regorafenib]]
:L01XE22 [[Masitinib]]
:L01XE23 [[Dabrafenib]]
:L01XE24 [[Ponatinib]]
:L01XE25 [[Trametinib]]
:L01XE26 [[Cabozantinib]]
:L01XE27 [[Ibrutinib]]
:L01XE28 [[Ceritinib]]
:L01XE29 [[Lenvatinib]]
:L01XE31 [[Nintedanib]]
:L01XE32 [[Cediranib]]
:L01XE33 [[Palbociclib]]
:L01XE34 [[Tivozanib]]
:L01XE35 [[Osimertinib]]
:L01XE36 [[Alectinib]]
:L01XE37 [[Rociletinib]]
:L01XE38 [[Cobimetinib]]
:L01XE39 [[Midostaurin]]
:L01XE40 [[Olmutinib]]
:L01XE41 [[Binimetinib]]
:L01XE42 [[Ribociclib]]
:L01XE43 [[Brigatinib]]
:L01XE44 [[Lorlatinib]]
:L01XE45 [[Neratinib]]
:L01XE46 [[Encorafenib]]
:L01XE47 [[Dacomitinib]]
:L01XE48 [[Icotinib]]
:L01XE50 [[Abemaciclib]]
:QL01XE91 [[Toceranib]]
 
==={{anchor|L01XX}}L01XX Other antineoplastic agents===
:L01XX01 [[Amsacrine]]
:L01XX02 [[Asparaginase]]
:L01XX03 [[Altretamine]]
:L01XX05 [[Hydroxycarbamide]]
:L01XX07 [[Lonidamine]]
:L01XX08 [[Pentostatin]]
:L01XX09 [[Miltefosine]]
:L01XX10 [[Masoprocol]]
:L01XX11 [[Estramustine]]
:L01XX14 [[Tretinoin]]
:L01XX16 [[Mitoguazone]]
:L01XX17 [[Topotecan]]
:L01XX18 [[Tiazofurine]]
:L01XX19 [[Irinotecan]]
:L01XX22 [[Alitretinoin]]
:L01XX23 [[Mitotane]]
:L01XX24 [[Pegaspargase]]
:L01XX25 [[Bexarotene]]
:L01XX27 [[Arsenic trioxide]]
:L01XX29 [[Denileukin diftitox]]
:L01XX32 [[Bortezomib]]
:L01XX33 [[Celecoxib]]
:L01XX35 [[Anagrelide]]
:L01XX36 [[Oblimersen]]
:L01XX37 [[Sitimagene ceradenovec]]
:L01XX38 [[Vorinostat]]
:L01XX39 [[Romidepsin]]
:L01XX40 [[Omacetaxine mepesuccinate]]
:L01XX41 [[Eribulin]]
:L01XX42 [[Panobinostat]]
:L01XX43 [[Vismodegib]]
:L01XX44 [[Aflibercept]]
:L01XX45 [[Carfilzomib]]
:L01XX46 [[Olaparib]]
:L01XX47 [[Idelalisib]]
:L01XX48 [[Sonidegib]]
:L01XX49 [[Belinostat]]
:L01XX50 [[Ixazomib]]
:L01XX51 [[Talimogene laherparepvec]]
:L01XX52 [[Venetoclax]]
:L01XX53 [[Vosaroxin]]
:L01XX54 [[Niraparib]]
:L01XX55 [[Rucaparib]]
:L01XX56 [[Etirinotecan pegol]]
:L01XX57 [[Plitidepsin]]
:L01XX58 [[Epacadostat]]
:L01XX59 [[Enasidenib]]
:L01XX60 [[Talazoparib]]
:L01XX61 [[Copanlisib]]
:QL01XX91 [[Tigilanol tiglate]]
 
==={{anchor|L01XY}}L01XY Combinations of antineoplastic agents===
:L01XY01 Cytarabine and daunorubicin
 
==References==
{{Reflist}}
{{adapted}}
{{Intracellular chemotherapeutic agents}}
{{Extracellular chemotherapeutic agents}}
[[Category:ATC codes|L01]]
[[Category:Antineoplastic drugs| ]]

Revision as of 02:13, 2 January 2025


Introduction

ATC code L01 is a classification used in the Anatomical Therapeutic Chemical Classification System to categorize antineoplastic agents. These are drugs used in the treatment of cancer, and they work by inhibiting the growth and spread of malignant cells. The ATC system is maintained by the World Health Organization (WHO) and is used globally to ensure uniformity in the classification of drugs.

Classification

ATC code L01 is divided into several subgroups based on the mechanism of action and chemical structure of the antineoplastic agents. These subgroups include:

L01A: Alkylating Agents

Alkylating agents work by adding an alkyl group to the DNA of cancer cells, which interferes with their replication and leads to cell death. Common drugs in this category include:

L01B: Antimetabolites

Antimetabolites resemble natural substances within the cell, thus interfering with normal cellular processes. They are particularly effective during the S phase of the cell cycle. Examples include:

L01C: Plant Alkaloids and Other Natural Products

These agents are derived from plants and work by disrupting the mitotic spindle formation, thus inhibiting cell division. Notable drugs include:

L01D: Cytotoxic Antibiotics and Related Substances

Cytotoxic antibiotics are compounds that have antibiotic properties but are used in cancer treatment due to their ability to damage the DNA of cancer cells. Examples are:

L01E: Protein Kinase Inhibitors

These inhibitors target specific protein kinases involved in the signaling pathways that regulate cell division and survival. They are a part of targeted cancer therapies. Examples include:

L01X: Other Antineoplastic Agents

This category includes antineoplastic agents that do not fit into the other categories. Examples include:

Mechanism of Action

Antineoplastic agents work through various mechanisms to inhibit the proliferation of cancer cells. These mechanisms include:

Clinical Use

Antineoplastic agents are used in the treatment of various types of cancer, including but not limited to:

The choice of agent depends on the type of cancer, stage of disease, and the patient's overall health status.

Side Effects

The use of antineoplastic agents is associated with a range of side effects due to their impact on rapidly dividing cells. Common side effects include:

Conclusion

ATC code L01 encompasses a diverse group of drugs that are essential in the management of cancer. Understanding their classification, mechanism of action, and clinical application is crucial for optimizing cancer treatment and improving patient outcomes.

References

  • World Health Organization. "ATC/DDD Index 2023." Accessed October 2023.
  • National Cancer Institute. "Cancer Drug Information." Accessed October 2023.

See Also